Nov 4, 4:10 PM ET
Acadia Healthcare reported third-quarter 2026 revenue of $895.3 million, up 5.1% from a year earlier, while net income attributable to the company fell to $34.5 million, or $0.38 per diluted share, from $0.40. The company raised its full-year 2026 guidance for adjusted EBITDA and adjusted earnings per share, but the quarter included a $13.4 million favorable benefit from a Florida supplemental payment program accrual. Shareholders see higher revenue and a higher outlook alongside lower per-share profit in the quarter.
- Q3 2026 revenue was $895.3 million, up 5.1%; same-facility revenue rose 5.2%.
- Net income attributable to Acadia was $34.5 million, or $0.38 per diluted share, versus $0.40 a year earlier; adjusted EPS was $0.60 versus $0.72.
- Full-year 2026 adjusted EPS guidance was raised to $1.70 to $1.80 from $1.45 to $1.60; adjusted EBITDA guidance was raised to $615 to $625 million from $590 to $615 million.
- Net leverage ratio was 3.9x Adjusted EBITDA as of September 30, 2026; cash and cash equivalents were $163.3 million.
Read the filing on SEC.gov ↗
Jul 28, 4:57 PM ET
Acadia Healthcare reported second-quarter 2026 results on July 28, 2026. Revenue was $865.8 million, roughly flat from a year earlier, while net income attributable to Acadia fell to $10.9 million, or $0.12 per diluted share, from $30.1 million, or $0.33, and Adjusted EBITDA dropped 26% to $149.2 million, including a $28.6 million professional and general liability reserve adjustment. The company raised the low end of its full-year 2026 ranges for revenue, Adjusted EBITDA, Adjusted EPS and operating cash flow, and lowered the top end of its capital expenditure range, which matters to shareholders because it shows weaker quarterly profit alongside a modestly higher outlook.
- Revenue $865.8 million vs. $869.2 million in Q2 2025; same-facility revenue flat year over year
- Net income attributable to Acadia $10.9 million, or $0.12 per diluted share, vs. $30.1 million, or $0.33, a year earlier
- Full-year 2026 Adjusted EPS guidance $1.45 to $1.60, up from $1.35 to $1.60 in April; Adjusted EBITDA $590 million to $615 million vs. $580 million to $615 million
- Conference call scheduled for Wednesday, July 29, 2026, at 9:00 a.m. Eastern Time
Read the filing on SEC.gov ↗
Apr 29, 5:22 PM ET
Acadia Healthcare reported first-quarter 2026 revenue of $828.8 million, up 7.6% from a year earlier, but reported and adjusted earnings per diluted share both fell. The company raised its full-year 2026 adjusted EBITDA and adjusted EPS guidance and issued second-quarter guidance, which matters to shareholders because the higher outlook is set against lower quarterly per-share earnings.
- Revenue was $828.8 million, up 7.6%; same-facility revenue rose 7.3%
- Reported EPS was $0.05 versus $0.09; adjusted EPS was $0.37 versus $0.40
- Full-year 2026 adjusted EBITDA guidance raised to $580 to $615 million from $575 to $610 million
- Full-year adjusted EPS guidance raised to $1.35 to $1.60 from $1.30 to $1.55; second-quarter revenue guidance is $835 to $850 million
Read the filing on SEC.gov ↗
Apr 23, 4:20 PM ET
Acadia Healthcare said CFO Todd Young will resign effective April 30, 2026, to take a CFO role at a private equity-backed animal health company. The board appointed former CFO David Duckworth as interim CFO effective May 1, 2026, and the company reaffirmed its first-quarter and full-year 2026 guidance, so the financial outlook is unchanged.
- Todd Young resigns as CFO effective April 30, 2026, and will join the first-quarter earnings call on April 30.
- David Duckworth, CFO from July 2012 to July 2023, becomes interim CFO effective May 1, 2026, and is expected to serve at least until a permanent CEO is named.
- Duckworth's employment agreement sets a base salary at a monthly rate of $100,000 and a quarterly cash bonus of $125,000.
- Guidance reaffirmed: full-year 2026 revenue of $3.37 to $3.45 billion and adjusted EPS of $1.30 to $1.55; first-quarter results due after the close on April 29.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.